Evaluating biomarkers for detecting prostate cancer
Evaluation of the Performance of the Glycoscore Biomarkers for the Detection of Clinically Significant Prostate Cancer
This study is testing three new blood markers to see if they can help detect prostate cancer better in men who might have it or are being monitored for it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 137 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Medtechtomarket Consulting Ltd Industry-sponsored |
| Locations | 1 site (Liverpool) |
| Trial ID | NCT06554587 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the sensitivity and specificity of three glycoprotein biomarkers for the detection of clinically significant prostate cancer. Conducted by GlycoScore Dx Limited, the study will analyze venous blood samples from male patients suspected of having prostate cancer or those on active surveillance. The biomarkers will be evaluated individually and in combination with the prostate-specific antigen (PSA) test to identify the most effective diagnostic approach. The findings could lead to the development of a new GlycoScore test that improves prostate cancer detection.
Who should consider this trial
Good fit: Ideal candidates for this study are male patients aged 18 and over who are being investigated for suspected prostate cancer or are on active surveillance.
Not a fit: Patients with an active urinary tract infection, a prior diagnosis of any other cancer, or those currently receiving cancer treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prostate cancer diagnostics, reducing unnecessary biopsies and improving patient outcomes.
How similar studies have performed: While the approach of using biomarkers for prostate cancer detection is established, the specific combination of glycoproteins being evaluated in this study is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male patients aged 18 years and over * The patient is being investigated for suspected prostate cancer or is on active surveillance * The patient is able to give consent to take part in the study Exclusion Criteria: * A patient who has already taken part in the study * A patient with an active urinary tract infection * The patient has a prior diagnosis of any other cancer or is receiving any cancer treatment (including ADT) * The patient is currently or within the last 4 months enrolled on another study involving an investigational medicinal product
Where this trial is running
Liverpool
- Royal Liverpool University Hospital — Liverpool, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Henry P Lazarowicz, FRCS(Urol) — Liverpool University Hospitals NHS Foundation Trust
- Study coordinator: Rebecca Newman, BSc
- Email: rebecca.newman@medtechtomarket.com
- Phone: 07595 298 248
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.